علاج سرطان الغدة الدرقية الجريبي في سرطان الغدة الدرقية الجريبي الغازي على نطاق واسع

References

DOI: 10.1530/ETJ-24-0146

• Since the prognosis of patients with widely invasive FTC is significantly poorer compared to patients with minimally invasive FTC, completion total thyroidectomy with radioactive iodine (RAI) therapy for widely invasive FTC to detect the appearance of distant and local metastasis is strongly recommended in clinical practice guidelines.
• Multi-tyrosine kinase inhibitors such as sorafenib and lenvatinib are utilized for treating RAI-refractory FTCs.
• Anti-angiogenic drugs are multikinase inhibitors, including sorafenib, lenvatinib, and cabozantinib.
• Targeted agents include selective RET inhibitors (selpercatinib or pralsetinib) for FTCs harboring RET fusions or RET mutations, NTRK inhibitors (entrectinib and larotrectinib) for FTCs with NTRK fusions, and the BRAF/MEK inhibitor combination (dabrafenib/trametinib) for FTCs with BRAF V600E mutations.
• Furthermore, pembrolizumab is considered for FTCs with a tumor mutational burden.